Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Roquefort Investments PLC ( (GB:ROQ) ).
Roquefort Therapeutics has announced an extension of the deadline for completing the sale of its subsidiary, Lyramid Pty Ltd, to Pleiades Pharma Limited. The extension, now set for 31 October 2025, allows Pleiades to finalize its fundraising efforts with investors from the Gulf Cooperation Council. Upon completion, Roquefort will receive shares in Pleiades and potentially up to $2 million in cash. A new holding company, Midkine Investments Ltd, has been established to manage these shares, benefiting existing Roquefort shareholders. This transaction is part of Roquefort’s strategic plans to acquire clinical-stage assets and revenue-generating life science businesses.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the London Stock Exchange, focusing on developing first-in-class medicines in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes five novel patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 1,166,306
Technical Sentiment Signal: Sell
Current Market Cap: £1.97M
For a thorough assessment of ROQ stock, go to TipRanks’ Stock Analysis page.